Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 20;12(3):e0174360.
doi: 10.1371/journal.pone.0174360. eCollection 2017.

The HIV care cascade: Japanese perspectives

Affiliations

The HIV care cascade: Japanese perspectives

Aikichi Iwamoto et al. PLoS One. .

Abstract

Japan has been known as a low HIV-prevalence country with a concentrated epidemic among high-risk groups. However, it has not been determined whether Japan meets the 90-90-90 goals set by the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO). Moreover, to date, the HIV care cascade has not been examined. We estimated the total number of diagnosed people living with HIV/AIDS (PLWHA) (n = 22,840) based on legal reports to the Ministry of Health, Labour and Welfare by subtracting the number of foreigners who left Japan (n = 2,273) and deaths (n = 2,321) from the cumulative diagnosis report (n = 27,434). The number of total undiagnosed PLWHA was estimated by age and sex specific HIV-positive rates observed among first-time blood donors between 2011-2015 in Japan. Our estimates show that 14.4% (n = 3,830) of all PLWHA (n = 26,670) were undiagnosed in Japan at the end of 2015. The number of patients retained in care (n = 20,615: 77.3% of PLWHA), the percentage of those on antiretroviral therapy (n = 18,921: 70.9% of PLWHA) and those with suppressed viral loads (<200 copies/mL; n = 18,756: 70.3% of PLWHA) were obtained through a questionnaire survey conducted in the AIDS Core Hospitals throughout the country. According to these estimates, Japan failed to achieve the first two of the three UNAIDS/WHO targets (22,840/26,670 = 85.6% of HIV-positive cases were diagnosed; 18,921/22,840 = 82.8% of those diagnosed were treated; 18,756/18,921 = 99.1% of those treated experienced viral suppression). Although the antiretroviral treatment uptake and success after retention in medical care appears to be excellent in Japan, there are unmet needs, mainly at the surveillance level before patients are retained in care. The promotion of HIV testing and treatment programs among the key affected populations (especially men who have sex with men) may contribute to further decreasing the HIV epidemic and achieving the UNAIDS/WHO targets in Japan.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Estimation of diagnosed PLWHA as of December 31 2015.
(A)Cumulative diagnosis reports were collected from different data sources. (B)The number of foreigners who left Japan was estimated as written in “Materials and Methods” based on a previous report [27]. (C)Three different sources of deaths were available for non-coagulation disorders. The highest number (Hospital survey) was chosen to estimate the cumulative death number. % diagnosed was calculated based on the data in (A), (B), (C) and the number of undiagnosed PLWHA (Table 1). APL, AIDS Prevention Law; IDL, Infectious Disease Law; LCD, Leading Cause of Death.
Fig 2
Fig 2. HIV care cascade in Japan.
Columns in blue and the numbers and percentages above them show the care cascade using the number of PLWHA (26,670) as the denominator. The lines and percentages above them show the cascade calculated between the columns indicated by the lines.
Fig 3
Fig 3. Annually reported new HIV infections and % on ART in an AIDS Core Hospital.
Polygonal lines in black show the annually reported new HIV infections in Japan. Columns in blue show the percent of patients on ART in the IMSUT Hospital.

References

    1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337: 725–733. 10.1056/NEJM199709113371101 - DOI - PubMed
    1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337: 734–739. 10.1056/NEJM199709113371102 - DOI - PubMed
    1. Strategies for Management of Antiretroviral Therapy Study G, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355: 2283–2296. 10.1056/NEJMoa062360 - DOI - PubMed
    1. Masia M, Padilla S, Alvarez D, Lopez JC, Santos I, Soriano V, et al. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy. AIDS. 2013;27: 181–189. 10.1097/QAD.0b013e32835a1156 - DOI - PubMed
    1. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS. 2007;21: 685–692. 10.1097/QAD.0b013e32802ef30c - DOI - PubMed

Substances

LinkOut - more resources